PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33792658-8	2021	EC exposure to FG-4592, a prolyl hydroxylase inhibitor that increases hypoxia-inducible factor expression (HIFs), increased nmMYLK promoter activity, confirmed by HIF1alpha/HIF2alpha silencing.	roxadustat	15-22	hypoxia inducible factor 1, alpha subunit	Mus musculus	163-172	
33345685-6	2021	Additionally, roxadustat, a HIF prolyl-hydroxylase inhibitor, protected the renal tubular epithelial cells against iohexol-induced injury through stabilization of HIF1A and activation of downstream BNIP3-mediated mitophagy in vivo and in vitro.	roxadustat	14-24	hypoxia inducible factor 1, alpha subunit	Mus musculus	163-168	
33427060-8	2021	FG4592, a PHD inhibitor, increased HIF-1alpha and AQP2 protein abundance in association with decreased NFkappaB p65 protein expression in IMCD cells with H/R.	roxadustat	0-6	hypoxia inducible factor 1, alpha subunit	Mus musculus	35-45	
32726645-5	2020	FG-4592 treatment significantly upregulated HIF-1alpha and HO-1 and strikingly attenuated inflammation in vivo and in vitro.	roxadustat	0-7	hypoxia inducible factor 1, alpha subunit	Mus musculus	44-54	
32726645-8	2020	FG-4592 treatment remarkably ameliorated the LPS-induced lung injury through the stabilization of HIF-1alpha.	roxadustat	0-7	hypoxia inducible factor 1, alpha subunit	Mus musculus	98-108	
32534005-5	2020	Roxadustat ameliorated pulmonary fibrosis by reducing the pathology score and collagen deposition as well as decreasing the expression of collagen I, collagen III, PHD2, HIF-1alpha, alpha-SMA, CTGF, TGF-beta1 and p-Smad3/Smad3.	roxadustat	0-10	hypoxia inducible factor 1, alpha subunit	Mus musculus	170-180	
34652582-11	2022	These effects were partially ameliorated by inhibiting hypoxia-inducible factor 1alpha (HIF-1alpha) degradation via roxadustat administration in hypoxia-stimulated cardiomyocytes.	roxadustat	116-126	hypoxia inducible factor 1, alpha subunit	Mus musculus	55-86	
34652582-11	2022	These effects were partially ameliorated by inhibiting hypoxia-inducible factor 1alpha (HIF-1alpha) degradation via roxadustat administration in hypoxia-stimulated cardiomyocytes.	roxadustat	116-126	hypoxia inducible factor 1, alpha subunit	Mus musculus	88-98	
34652582-15	2022	Administration of roxadustat can partially reverse these harmful effects by stabilizing HIF-1alpha and inducing a metabolic shift toward glycolysis for energy production.	roxadustat	18-28	hypoxia inducible factor 1, alpha subunit	Mus musculus	88-98	
35597989-9	2022	The effects of roxadustat on the HIF-1alpha and Wnt/beta-catenin pathways were evaluated.	roxadustat	15-25	hypoxia inducible factor 1, alpha subunit	Mus musculus	33-43	
35620283-0	2022	Roxadustat, a Hypoxia-Inducible Factor 1alpha Activator, Attenuates Both Long- and Short-Term Alcohol-Induced Alcoholic Liver Disease.	roxadustat	0-10	hypoxia inducible factor 1, alpha subunit	Mus musculus	14-45	
35620283-10	2022	In vitro, we found roxadustat reduced inflammation and lipid accumulation mainly via HIF-1alpha regulation.	roxadustat	19-29	hypoxia inducible factor 1, alpha subunit	Mus musculus	85-95